About 52 per cent of employees experience burnout due to poor work-life balance, showed a survey conducted in five states in ...

Vertex Pharmaceuticals received an upgrade from StockNews.com, moving from a “hold” to a “buy” rating. Other analysts have ...

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company’s ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $502.92, with a +1.51% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...

This was the stock's second consecutive day of gains.

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...

For current and former smokers, statins may reduce the amount of chest muscle loss, while aspirin may contribute to increased chest muscle loss, according to a new study.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Vertex, Inc. (NASDAQ: VERX) has announced plans to host an Investor Day on Wednesday, March 19, in Philadelphia, PA. This ...